Reports
Sale
Global Diabetic Gastroparesis Treatment Market Size, Report: By Type: Surgical Treatment Products, Drugs; By Disease Indication: Compensated Gastroparesis, Gastric Failure, Others; By End User: Hospitals, Specialty Clinics, Homecare; By Route of Administration: Oral, Injectables; Regional Analysis; Supplier Landscape; 2024-2032
Global Diabetic Gastroparesis Treatment Market Outlook
The global diabetic gastroparesis treatment market size was valued at USD 3.64 billion in 2023, driven by the improvements in the arena of healthcare and gastric treatments. The market is anticipated to grow at a CAGR of 4.1% during the forecast period 2024-2032 to reach a value of USD 5.87 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Advancements in Healthcare and Gastric Treatments to Aid the Market Growth of Diabetic Gastroparesis Treatment
The market for diabetic gastroparesis treatment is being driven by the improvements in the arena of healthcare and gastric treatments. The market is further aided by the growing cases of diabetes across the globe. Further, the existence of a seamless healthcare industry lays emphasis on the swift treatment and diagnosis, which is also propelling the market forward. Diabetic gastroparesis severely affects the quality of life. Therefore, medical practitioners are showing tremendous concern for the patient while treating such disorders, consequently enhancing the market growth. In addition, the availability of dieticians and professionals who can advise the patient regarding proper food consumption and food habits is also contributing to the market growth of diabetic gastroparesis treatment. All these factors are expected to support the market growth over the forecast period as well.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Diabetic Gastroparesis Treatment: Market Segmentation
Diabetic gastroparesis treatment is the treatment for delayed gastric emptying related to diabetes. The condition is observed in patients suffering from type-1 and type-2 diabetes and is found to be frequent in female patients that are suffering from type-2 diabetes.
On the basis of type, the market is divided into:
- Surgical Treatment Products
- Drugs
Based on disease indication, the industry can be segmented into:
- Compensated Gastroparesis
- Gastric Failure
- Others
By distribution channel, the industry is categorised into:
- Hospital Pharmacies
- Drug Stores
- Private Clinics
- Retail Pharmacies
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Cases of Diabetes to Aid the Market Growth of Diabetic Gastroparesis Treatment
The diabetic gastroparesis treatment industry is being driven by the need to meet the evolving demands within the diabetic treatment and diagnostics sector. The market is further aided by the rising cases of type-I and type-II diabetes. Furthermore, the rising demand for minimally invasive treatments and surgeries for the diabetic gastroparesis is also providing an impetus to the market growth as it has created significant growth opportunities within the industry. Moreover, the development of new drug lines within the industry is expected to boost the market growth of diabetic gastroparesis treatment over the forecast period.
Key Industry Players in the Global Diabetic Gastroparesis Treatment Market
The report gives a detailed analysis of the following key players in the global diabetic gastroparesis treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Evoke Pharma, Inc.
- Allergan plc
- Salix Pharmaceuticals
- Theravance Biopharma, Inc.
- Medtronic, plc
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Disease Indication |
|
| Breakup by End User |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetic Gastroparesis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diabetic Gastroparesis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Diabetic Gastroparesis Epidemiology (2016-2031)
5.3 Europe Diabetic Gastroparesis Epidemiology (2016-2031)
5.4 Asia-Pacific Diabetic Gastroparesis Epidemiology (2016-2031)
5.5 Latin America Diabetic Gastroparesis Epidemiology (2016-2031)
5.6 Middle East & Africa Diabetic Gastroparesis Epidemiology (2016-2031)
6 Diabetic Gastroparesis Treatment Market Overview
6.1 Diabetic Gastroparesis Treatment Market Historical Value (2017-2023)
6.2 Diabetic Gastroparesis Treatment Market Forecast Value (2024-2032)
7 Diabetic Gastroparesis Treatment Market Landscape
7.1 Diabetic Gastroparesis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetic Gastroparesis Treatment Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Diabetic Gastroparesis Treatment Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Diabetic Gastroparesis Treatment Market Segmentation
9.1 Diabetic Gastroparesis Treatment Market by Type
9.1.1 Market Overview
9.1.2 Surgical Treatment Products
9.1.3 Drugs
9.2 Diabetic Gastroparesis Treatment Market by Disease Indication
9.2.1 Market Overview
9.2.2 Compensated Gastroparesis
9.2.3 Gastric Failure
9.2.4 Others
9.3 Global Gastroparesis Treatment Market by End User
9.3.1 Market Overview
9.3.2 Hospitals
9.3.3 Specialty Clinics
9.3.4 Homecare
9.4 Global Gastroparesis Treatment Market by Route of Administration
9.4.1 Market Overview
9.4.2 Oral
9.4.3 Injectables
9.5 Diabetic Gastroparesis Treatment Market by Region
9.5.1 Market Overview
9.5.2 North America
9.5.3 Europe
9.5.4 Asia Pacific
9.5.5 Latin America
9.5.6 Middle East and Africa
10 North America Diabetic Gastroparesis Treatment
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Diabetic Gastroparesis Treatment
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Diabetic Gastroparesis Treatment
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Diabetic Gastroparesis Treatment
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Diabetic Gastroparesis Treatment
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Evoke Pharma Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Allergen Pnc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Salix Pharmaceuticals
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Theravance Biopharma Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Medtronics pLC
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Abbot
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Rhythm Pharmaceuticals
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Allergen plc.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Astrazeneca plc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Cadila Pharmaceuticals
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Neurogastrx Inc
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Bausch Health
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
22 Diabetic Gastroparesis Treatment - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global diabetic gastroparesis treatment market reached a value of USD 3.64 billion in 2023.
The market is projected to grow at a CAGR of 4.1% during the forecast period of 2024-2032 to reach a value of USD 5.87 billion by 2032.
The major drivers of the industry, such as rising disposable incomes, increasing population, growing improvements in the arena of healthcare and gastric treatments, rising prevalence of diabetes, increasing availability of dieticians and professionals, and growing demand for minimally invasive treatments and surgeries for the diabetic gastroparesis, are expected to aid the market growth.
The key trends guiding the growth of the market include the rising development of new drugs and advancements in the healthcare industry.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading types of diabetic gastroparesis treatment in the industry are surgical treatment products and drugs.
The major disease indications in the market are compensated gastroparesis and gastric failure, among others.
The significant distribution channels in the industry are hospital pharmacies, drug stores, private clinics, and retail pharmacies, among others.
The major players in the industry are Evoke Pharma, Inc., Allergan plc, Salix Pharmaceuticals, Theravance Biopharma, Inc., and Medtronic, plc, among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER